A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics

American Journal of Clinical Pathology

Volumn 135, Issue 6, 2011, Pages 921-928

  King, Rebecca L ^a   Naghashpour, Mojdeh ^b   Watt, Christopher D ^a   Morrissette, Jennifer J D ^a   Bagg, Adam ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Acute leukemia; Complementary; Cytogenetics; False negative; Molecular; Multiplex; Reverse transcriptase polymerase chain reaction; RT PCR; Translocations

Indexed keywords

AFF1 PROTEIN; BCR ABL PROTEIN; CBFB PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MYH11 PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RARA PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ADULT; COHORT STUDIES; CYTOGENETIC ANALYSIS; FALSE NEGATIVE REACTIONS; HUMANS; LEUKEMIA; MOLECULAR BIOLOGY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 79957701784     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPJCW6BY0CNIHD     Document Type: Article

References (45)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2006:169-177.
3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-4083.
4. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetics abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336. (Pubitemid 35429670)
5. Haferlach T, Kern W, Schnittger S, et al. Modern diagnostics in acute leukemias. Crit Rev Oncol Hematol. 2005;56:223-234. (Pubitemid 41565551)
6. Grimwade D, Walker H, Oliver F, et al; for the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
7. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115-136. (Pubitemid 38380667)
8. Tellman MS, Rowe JM. Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid. Blood Rev. 1994;8:70-78.
9. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res. 2004;91:1-30. (Pubitemid 39140955)
10. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087-1094.
11. Byrd JC, Dodge RK, Carroll AJ, et al. Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767-3775.
12. Mistry AR, Pederson EW, Solomon E, et al. The molecular pathogenesis of acute promyelocytic leukemia: implications for the clinical management of the disease. Blood Rev. 2003;17:71-97. (Pubitemid 36372973)
13. Arber DA, Carter NH, Ikle D, et al. Value of combined morphologic, cytochemical, and immunophenotypic features in predicting recurrent cytogenetic abnormalities in acute myeloid leukemia. Hum Pathol. 2003;34:809-813.
14. Arber DA, Stein AS, Carter NH, et al. Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672-680. (Pubitemid 37046388)
15. Meyer-Monrad S, Parlier V, Passweg J, et al. Combination of broad molecular screening and cytogenetic analysis for genetic risk assignment and diagnosis in patients with acute leukemia. Leukemia. 2006;20:247-253. (Pubitemid 43148662)
16. Krauter J, Peter W, Pascheberg U, et al. Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol. 1998;103:72-78. (Pubitemid 28470802)
17. Association for Molecular Pathology. AMP test directory. http://www.amptestdirectory.org. Accessed July 30, 2010.
18. Rowe D, Cotterill SJ, Ross FM, et al. Cytogenetically cryptic AML1-ETO and CBFβ-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukemia. Br J Haematol. 2000;111:1051-1056. (Pubitemid 32104915)
19. Strehl S, Konig M, Mann G, et al. Multiplex reverse transcriptase- polymerase chain reaction screening in childhood acute myeloblastic leukemia. Blood. 2001;97:805-808. (Pubitemid 32113417)
20. Harrison CJ. The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukemia. Blood Rev. 2001;15:49-59. (Pubitemid 32506071)
21. Cross NC, Melo JV, Feng L, et al. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8:186-189. (Pubitemid 24032839)
22. Repp R, Borkhardt A, Haupt E, et al. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence based automatic DNA-fragment analysis. Leukemia. 1995;9:210-215.
23. Langabeer SE, Walker H, Rogers JR, et al, for the MRC Adult Leukaemia Working Party. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. Br J Haematol. 1997;99:925-928. (Pubitemid 28047161)
24. Langabeer SE, Walker H, Gale RE, et al, for the MRC Adult Leukaemia Working Party. Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the UK MRC AML trials. Br J Haematol. 1997;96:736-739.
25. Nordkamp LO, Mellink C, van der Schoot E, et al. Karyotyping, FISH, and PCR in acute lymphoblastic leukemia: competing or complementary diagnostics? J Pediatr Hematol Oncol. 2009;31:930-935.
26. Xu W, Li JY, Liu Q, et al. Multiplex fluorescence in situ hybridization in identifying chromosome involvement of complex karyotypes in de novo myelodysplastic syndromes and acute myeloid leukemia. Int J Lab Hematol. 2010;32:86-95.
27. Jalal SM, Law ME, Stamberg J, et al. Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. Br J Haematol. 2001;112:975-980. (Pubitemid 32322925)
28. Joyce CA, Ross FM, Dennis NR, et al. Multipaint FISH: a rapid and reliable way to define cryptic and complex abnormalities. Clin Genet. 1999;56:192-199. (Pubitemid 29494817)
29. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
30. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006;20:87-94.
31. Watt CD, Bagg A. Molecular diagnosis of acute myeloid leukemia. Expert Rev Mol Diagn. 2010;10:993-1012.
32. Salto-Tellez M, Shelat SG, Benoit B, et al. Multiplex RT-PCR for the detection of leukemia-associated translocations. J Mol Diagn. 2003;5:231-236.
33. Weatherill CR, Bagg A, Nielsen D, et al. Rapid leukemia subtyping by liquid bead array: clinical assessment of Signature LTx [abstract]. J Mol Diagn. 2005;7:647.
34. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-totreat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232-1240. (Pubitemid 36988027)
35. Stentoft J, Hokland P, Ostergaard M, et al. Minimal residual core binding factor AMLs by real time quantitative PCR: initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30:389-395. (Pubitemid 43254960)
36. Hutchings-Hoffmann M, Wirenfeldt Klausen T, Hasle H, et al. Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significance. Haematologica. 2005;90:984-986. (Pubitemid 41020305)
37. Choughule A, Polampalli S, Amre P, et al. Identification of PML/RARα fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization. Genet Mol Res. 2009;8:1-7.
38. Gamerdinger U, Teigler-Schlegel A, Pils S, et al. Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions. Genes Chromosomes Cancer. 2003;36:261-272. (Pubitemid 36158199)
39. Olesen LH, Clausen N, Dimitrijevic A, et al. Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients. Br J Haematol. 2004;127:59-66. (Pubitemid 39331107)
40. Reiter E, Greinix H, Rabitsch W, et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3) (q21q26) or homologous translocation t(3;3)(q21;q26). Ann Hematol. 2000;79:374-377.
41. Bernstein J, Dastugue N, Haas OA, et al. Nineteen cases of the t(1;22)(p13q13) acute megakaryoblastic leukemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia. 2000;14:216-218. (Pubitemid 30068396)
42. Duchayne E, Fenneteau O, Pages MP, et al. Acute megakaryoblastic leukemia: a national clinical and biological study of 53 adult and childhood cases by the group Français d'Hematologie Cellulaire (GFHC). Leuk Lymphoma. 2003;44:49-58. (Pubitemid 36113829)
43. Chi Y, Lindgren V, Quigley S, et al. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med. 2008;132:1835-1837.
44. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431-448.
45. Mrozek K, Harper D, Aplan P. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:991-1010.